Drug Profile
VVX 001
Alternative Names: VVX-001; VXX 001Latest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator Viravaxx
- Class Antivirals; Recombinant fusion proteins; Vaccines
- Mechanism of Action Immunostimulants; Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 30 Jan 2024 Updated efficacy and adverse event data from a phase I/II trial in Hepatitis B released by Viravaxx
- 30 Jan 2024 Viravaxx completes a phase II trial in Hepatitis B (In volunteers) in Austria (SC, Injection) (NCT03625934)
- 25 Aug 2022 Efficacy data from a phase I/II trial in Hepatitis B presented at the International Liver Congress 2022 (ILC-2022)